Effectiveness of preformed foot orthoses in reducing lower limb pain, swollen and tender joints and in improving quality of life and gait parameters in children with juvenile idiopathic arthritis: a randomised controlled trial (Protocol) by Fellas, Antoni et al.





background Many children and adolescents with 
juvenile idiopathic arthritis experience lower limb problems 
which may lead to physical disabilities significantly 
impacting on their quality of life and symptoms. Emerging 
evidence has identified the effective role of podiatry in the 
management of juvenile idiopathic arthritis, suggesting the 
clinical benefit of different orthotic therapies.
Methods This study will be a parallel-group designed, 
multicentre, randomised controlled trial, aiming to recruit 
66 children and adolescents with juvenile idiopathic arthritis 
aged between 5 and 18 years. Those recruited will need 
to be diagnosed according to the International League of 
Associations for Rheumatology criteria, and present with 
lower limb joint pain, swelling and/or tenderness. Participants 
will be recruited from three outpatient hospital clinics in New 
South Wales, Australia. Participants will be randomly allocated 
to receive a trial or control intervention. The trial group will be 
prescribed a customised preformed foot orthoses; instead, 
the control group will receive a flat 1 mm insole with no 
corrective modifications. Primary outcome measure recorded 
will be pain. Secondary outcomes will be quality of life, foot 
disability, swollen and tender joint count and gait parameters 
(such as plantar pressures, walking speed, stance and swing 
time). The allocated foot orthoses will be worn for 12 months, 
with data collected at baseline, 4 weeks, 3, 6 and 12 months 
intervals. Group allocation will be concealed and all analyses 
will be carried out on an intention to treat.
Discussion The purpose of this trial is to explore 
the efficacy of a cost-effective, non-invasive podiatric 
intervention that will be prescribed at the initial 
biomechanical consultation. This approach will promote 
early clinical intervention, which is the gold standard in 
paediatric rheumatology. Furthermore, this study has the 
potential to provide new evidence for the effectiveness 
of a mechanical intervention alone to reduce swollen and 
tender joints in juvenile idiopathic arthritis.
trial registration number This clinical trial has 
been registered with the Australian New Zealand Clinical 
Trials Registry: ACTRN12616001082493p. Ethics for 
this randomised controlled trial has been approved 
(16/09/21/4.03).
IntroDuctIon
Juvenile idiopathic arthritis (JIA) is the most 
common chronic rheumatic disease that 
affects children and adolescent and may 
cause short-term and long-term disability.1 
Prevalence estimated in high-income coun-
tries range from 16 to 400 per 1 00 000.1 2 The 
lower limb appears to be more commonly 
involved in JIA, particularly the oligoar-
ticular subtype.1 3 The manifestation of JIA 
includes joint swelling, effusion, tenderness 
and painful limitation with joint movement, 
discrepancies in limb development and 
What this study hopes to add?
This study may inform clinical practice on the 
benefit of prescribing a customised preformed foot 
orthoses as part of a multidisciplinary approach, in 
the management of lower limb problems in juvenile 
idiopathic arthritis.
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Protocol
What is known about the subject?
Custom or customised foot orthoses may reduce lower 
limb pain and improve quality of life in children with 
juvenile idiopathic arthritis. No research has explored 
the effectiveness of a mechanical intervention alone 
for reducing swollen and tender lower limb joints in 
juvenile idiopathic arthritis.
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fatigue.1 4 Lower limb impairments may reduce physical 
activities compared with healthy children.5–7 As a result, 
this may account for the lower aerobic capacity among 
children with JIA.8 Initially, the main aim for the multi-
disciplinary team should be to relieve pain and discom-
fort, to reduce joint inflammation, promote function and 
prevent deformities. However, the provision of healthcare 
to children with JIA has been reported to be particularly 
challenging,9–12 with podiatric care currently very limited 
within paediatric rheumatology in Australian hospitals.
Few studies have evaluated the effectiveness of a 
custom or customised preformed foot orthoses (FOs) in 
children with JIA.13 14 A meta-analysis of the effectiveness 
of a custom or customised FOs in children with JIA indi-
cated that FOs may hold clinical importance in outcomes 
such as pain and quality of life; however, between-group 
differences in means were predominately insignificant 
with imprecise and broad CIs.15 Moreover, a randomised 
controlled trial investigating the effectiveness of a multi-
disciplinary foot care programme found no statistical 
significant difference between groups.16 The programme 
included a multifaceted approach to foot care in JIA; 
including ultrasound-guided intracorticosteroid injec-
tions, paediatric rheumatology, podiatry and physio-
therapy.16 The authors reported challenges in participant 
recruitment and retention; leading to an underpowered 
study which may have been vulnerable to type II error.16 
Until more research is conducted, the effectiveness of 
FOs in children with JIA remains to be further explored.15 
A recent study in patients with early rheumatoid arthritis 
suggests that by correcting biomechanical misalignments 
and reducing mechanical trauma of foot and ankle joints 
using a customised preformed FOs, it may result in a 
reduction of swelling and joint tenderness.17 The effec-
tiveness of a customised preformed FOs alone for the 
reduction of lower limb swollen and tender joints in JIA 
has never been investigated. This randomised controlled 
trial aims to provide new evidence on the effectiveness of 
a non-invasive, mechanical therapy for the reduction of 
swollen and tender joint counts in children with JIA. It 
will also further explore the effectiveness of customised 
preformed FOs in reducing lower limb pain, improving 
quality of life and gait parameters in children and adoles-
cents affected by this rheumatic disease.
objectIves
The objective of this study is to investigate the effective-
ness of a customised preformed FOs in reducing lower 
limb pain, swollen and tender joints and in improving 
quality of life and gait in children with JIA.
HypotHeses
primary outcomes
Preformed FOs will reduce lower limb pain using visual 
analogue scale (VAS) in children with JIA.
secondary outcomes
1. Preformed FOs will improve quality of life in 
children with JIA using the Pediatric Quality of 
Life Questionnaire (PedsQL) Rheumatology 
Module—V.3.0 for children and parents.
2. Preformed FOs will improve foot disability in children 
with JIA using the Juvenile Arthritis Foot Disability In-
dex (JAFI).
3. Preformed FOs will reduce localised swelling and ten-
derness of lower limb joints in children with JIA by 
visual inspection and palpation.
4. Preformed FOs will have an effect on quantitative 
kinematic and kinetic parameters of gait in children 
with JIA when barefoot, with shoes alone, and with 
shoes and FOs.
trial design
To test the hypothesis, this study will be a parallel-group 
designed, multicentre, randomised controlled trial. The 
allocation ratio of participants to their groups will be 1:1.
MetHoDology
study setting
This randomised controlled trial will be conducted across 
three outpatient paediatric rheumatology clinics in New 
South Wales, Australia: John Hunter Children’s Hospital 
(Newcastle); Sydney Children’s Hospital Network (Rand-
wick and Westmead).
eligibility criteria
The inclusion and exclusion criteria are as follows:
Inclusion criteria
 ► Diagnosed with JIA according to the International 
League of Associations for Rheumatology criteria.
 ► Aged 5–18 years.
 ► Active involvement of the lower limb (including foot/
ankle and/or hip and knee involvement).
 ► No previous use of FOs, or previous failure of foot or-
thotic management, where the patient has not worn 
any FOs for a period of at least 3 months.
 ► If disease-modifying antirheumatic drugs and/or bi-
ological therapy are used, not having started these 
drug therapies within 6 months of enrolling in the 
trial.
Exclusion criteria
 ► Inability to walk barefoot or shod for 15 m without 
assistive devices.
 ► Concomitant musculoskeletal disease, central or pe-
ripheral nerve disease and endocrine disorders, in-
cluding diabetes mellitus.
 ► History of lower limb surgery that required general 
anaesthetic.
 ► Currently using FOs.
 ► Where prescription of FOs is contraindicated, for 
example, significant osseous abnormalities noted in 
the lower limbs and/or vertebrae during the physical 
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Figure 1 Swollen lower limb joint count.
Figure 2 Tender lower limb joint count.
evaluation. Unwillingness to wear appropriate foot-
wear for fitting orthoses.
control group
Participants in the control group will receive a flat insole 
without any corrective modifications. The control insole 
will be made with 1 mm thick leather board, top covered 
by a ‘Dual Opulex Performance’ 1.5 mm thick material 
made from a neoprene base and a stretch nylon top. The 
top cover is representative of standard insole appearance 
regularly supplied by podiatrists.
trial group
The trial group will receive a customised, pre-formed FOs 
with the same ‘Dual Opulex Performance’ top cover. The 
prescription of the FOs (SlimFlex Simple, Algeos) will 
be customised at chair side according to each individual 
biomechanical need, and supplied on the same day of 
the initial assessment. Supplying the FOs on the same day 
of the initial assessment promotes early clinical interven-
tion, which is the gold standard approach in JIA.1 18 Chief 
investigator (AF) will issue the trial and control orthoses 
to participants.
Footwear
Participants in both the control and trial group will receive 
footwear education and recommendations. Footwear 
advice will focus on suitable cushioning properties and 
supportive features of a shoe, appropriate sizes and details 
related to orthoses fitting. Information will be conveyed in 
a manner that is easy to understand for both participants 
and their parents.
usual care
Throughout the duration of the trial, participants in both 
the control and trial groups will continue their usual 
outpatient care at the John Hunter Children’s Hospital 
and Sydney Children’s Hospital Network. Outpatient care 
may include but not limited to a paediatric rheumatologist, 
specialist nurse, physiotherapist, occupational therapist, 
psychologist, etc.
compliance/adherence
Adherence to the control and trial intervention will be 
monitored with visual inspection of FOs at follow-up consul-
tations. Participants will be asked to fill a self-reported diary 
that will have to be completed for the duration of the trial 
in order to record the overall number of days per week they 
have worn their FOs. Participants will be required to bring 
their diary to their next follow-up consultation and will be 
given a new one to complete and return. Chief investigator 
(AF) will provide verbal and written instructions to both 
participants and parent on how to correctly wear the FOs, 
as well as clinical support if any problems arise. In case, 
patient’s foot size will increase during the data collection 
period and become unsuitable, the exact same prescrip-
tion will be replicated in a new longer device and supplied 
to the participant.
Pharmaceutical changes will be recorded over the 
12-month period. If changes occur to participant’s medi-
cations, it will be noted and patients will be classified as 
‘medication changed’. This approach is fundamental to 
account for any positive effect to be solely attributed to 




Participants in both groups will be asked to rate their 
lower limb pain on a 100 mm VAS. Pain will be self-re-
ported by participants and their parents/carer. A clinical 
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Figure 3 Participant timeline. FOs, foot orthoses.
important difference is considered when there is an 
8 mm difference between time intervals.19 When meas-
uring pain with the 100 mm VAS, a lower score indicates 
less pain and therefore is a better outcome. Pain scores 
will be collected at baseline, 4 weeks, 3, 6 and 12 months 
follow-up consultations, with 12 months representing the 
end point for primary outcome assessment.
Secondary outcomes
Quality of life
Quality of life will be measured using the PedsQL. The 
PedsQL (module 3) is a self-reported questionnaire, which 
will be independently supplied to both the participants and 
parents/carer.20 The PedsQL V.3.0 Rheumatology Module is 
specific for children with JIA by measuring different outcome 
subheadings such as: ‘pain and hurt’, ‘daily activities’, ‘treat-
ment’, ‘worry’ and ‘communication’.20 A clinical important 
difference is considered when there is a 5-point difference 
between time intervals.20 The PedsQL questionnaire is scored 
out of 100 points, and a higher score is indicative of a better 
quality of life. The PedsQL is available in different age ranges: 
5–7; 8–12 and 13–18. Quality of life is self-assessed and will 
be measured at baseline and 3, 6 and 12 months time point.
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Figure 4 Pathway for FOs customisation.
Foot disability
Foot disability will be measured using the JAFI, which 
comprises 3 components (27 responses in total): foot 
and ankle impairment, activity limitation and participa-
tion restriction.21 The JAFI has shown to be a reliable and 
valid measure of foot-related disability in children with 
JIA.21 Foot disability using the JAFI will be measured at 
baseline and 3, 6 and 12 months time.
Swollen and tender joint
Helliwell et al22 developed a tool to record swollen and 
tender foot and ankle joints specifically for adult rheu-
matoid arthritis.22 This tool was used in an earlier podiat-
ric-based study in rheumatoid arthritis17; and with some 
further modifications (adding hip, knee, distal and prox-
imal interphalangeal joints), will be used to assess lower limb 
joint swelling and tenderness count for this randomised 
controlled trial. Joint count for swelling and tenderness 
will be recorded at baseline and 6-months follow-up assess-
ments. The assessment tools for swelling and tenderness 
are depicted in figures 1 and 2, respectively. Physical exam-
ination will be carried out by paediatric rheumatologists 
DSG/JC who will be blinded to the participant’s treatment 
allocation. 
Gait parameters
Gait analysis will be completed at baseline, 3 and 6 
months. In-shoe and plantar pressure analysis will be 
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carried out by using the latest Wireless F-Scan and HR 
Mat (Tekscan, Boston, USA), respectively. Both systems 
are equipped with the same sensors resolution allowing 
for calibration and data analysis comparison. Barefoot, 
shod and shoes with the FOs recordings sequence will 
be randomised to account for fatigue potentially exhib-
ited by children with symptomatic JIA during acquisi-
tion of gait data. Outcome measures for gait parame-
ters include:
a. Peak pressure and pressure time integral data will be 
extrapolated from the following anatomical areas: 
total contact; heel; midfoot; rearfoot; first metatarsal 
head; second metatarsal head; third/fourth metatarsal 
head; fifth metatarsal head; lesser digits; distal phalanx 
of hallux.
b. Walking speed (m/s)
c. Stance time (s)
d. Swing time (s)
e. Double limb support (s)
f. Stride length (cm)
Biomechanical assessment
Standardised assessments such as the Foot Posture Index 
will be conducted to clinically assess the lower limb, 
and inform the prescription and modifications of foot 
orthoses. Muscle bulk and limb length discrepancies 
will be observed and recorded as part of the Paediatric 
Gait Arms Legs Spine (pGALS) Legs assessment. The 
following additional biomechanical and anatomical test 
will be carried out: range of motion of lower limb joints; 
gait analysis; presence of enthesitis (Achilles and plantar 
fascia) and presence of tendonitis (eg, tibialis posterior, 
peroneal and Achilles tendons).
timeline of participants
Participants will only be required to attend three data 
collection sessions: baseline, 3 and 6 months (4-week 
and 12-month follow-ups are self-assessed only); and it 
is expected that each meeting will last no more than 
1 hour. Participants, in both groups, will be supplied 
their allocated FOs at the same day of baseline assess-
ment and will be required to wear their FOs for 12 
months. Figure 3 depicts a schematic diagram of the 
participant timeline.
sample size
Currently, there are insufficient data to conduct power 
calculations for each outcome. However, sufficient data 
are available with regard to pain outcome. Power calcula-
tions are therefore based on the outcome of pain measured 
on a 100 mm VAS, with a minimal clinical significance of 
8 mm.19 For a two-sided t-test with α=0.05 and power 80% 
for a randomised controlled trial design with baseline and 
primary outcome of difference between the groups at 
12 months, and a moderate effect size of 0.6, it was esti-
mated that a total of 90 participants would be required 
(45 controls and 45 trial) on a ratio of 1:1 allocation.23 24 
This was adjusted with an analysis of covariance using an 
assumed correlation of 0.6 giving an adjusted total number 
of participants required of 60 (30 controls and 30 trial). 
The study will be overpowered to an estimated 66 (ie, 33 
participants per group) to allow for 10% dropouts during 
the 12-month data collection period.
recruitment
Participants will be recruited from the outpatient paedi-
atric rheumatology clinics listed in the study setting 
section. Parents and patient will be asked if they would 
like to be part of the study when attending their sched-
uled consultation with the paediatric rheumatologist. 
If the patients are eligible and their parents/carers are 
interested in being involved they will then be referred to 
the chief investigator (AF).
Allocation
Sequence generation
Immediately after consent is obtained, participants 
will be randomly allocated in blocks of 10, to either a 
control or trial group. Their allocation to each group 
will be achieved with a predetermined randomly 
generated list. This will be achieved using a computer 
random number generator (https://www. random. org/ 
sequences/).
Allocation concealment
Allocation concealment will be achieved by using 
sequentially numbered, opaque and sealed envelopes. 
Both sequence generation and allocation concealment 
will be conducted by a research team member. During 
this independent allocation process, the research team 
member will not be involved at any stage as part of 
the recruitment process, orthotic prescription of the 
control or trial intervention, data collection and will 
not have any prior or ongoing contact with enrolled 
participants.
blinding
Participants and their carer’s in both groups will be blinded 
to what intervention they receive. The external aesthetic 
appearance of both the control and trial FOs will be the 
same by using the ‘Dual Opulex Performance’ top cover. To 
reduce bias during the data analysis stage, once data collec-
tion is complete, the participants' and parents‘/carers’ 
identity and their intervention will be coded and deidenti-
fied. Outcome assessors will be blinded to all self-reported 
outcomes such as pain (VAS), quality of life (PedsQL) and 
foot disability (JAFI).
Data analysis
All data collected during the study from baseline, 4 weeks, 
3, 6 and 12 months will be represented graphically using 
the histograms and/or box plots. Normality will be 
checked using the Shapiro-Wilk test. Where the variable 
presents ordinal data, the appropriate non-parametric 
test will be used. A series of between-group and with-
in-group analyses will be carried out. Analyses will be 
conducted with intention to treat.
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Comparison between control and trial group
To test the hypothesis, the control group will be 
compared with the trial group. Pair-wise statistical 
analysis will be carried out using an unpaired t-test or 
Mann-Whitney U test, depending on the distribution 
of the data.
Within each individual group analysis
To investigate the relationships between the groups at 
baseline, 4-weeks, 3, 6 and 12 months, a repeated meas-
ures analysis of variance will be carried out for para-
metric data where sphericity exist; or a Friedman test 
where non-parametric and/or no-sphericity exists.
limitations
Few limitations should be noted as part of this protocol. 
Joint disease in JIA may be subclinical and therefore may 
not be detected using physical examination alone. The 
use of a standardised lower limb physical examination 
tool may improve the validity of findings in the swollen 
and tender joint outcome. Lastly, the orthoses interven-
tion will vary based on the individual biomechanical 
needs of each participants and therefore may differ. In 
order to enhance the reproducibility of the trial interven-
tion, each FO modifications will be standardised using a 
clinical decision pathway (figure 4).
Data management
All electronic data will be kept on a University approved 
and prescribed laptop that will be password protected. 
The data will also be stored on a backup external hard 
drive that will be under lock and key in a metal cabinet 
on the University premises. The information from the 
research project will be stored for a period of 5 years 
after the completion of the research project, in accord-
ance with the University of Newcastle’s ‘stored data policy 
S000922’.
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